Kyverna Therapeutics Net Profit Margin 2023-2024 | KYTX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

Kyverna Therapeutics net profit margin from 2023 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

Kyverna Therapeutics net profit margin from 2023 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$171.8B
Vertex Pharmaceuticals (VRTX)	$117.5B
Regeneron Pharmaceuticals (REGN)	$111.6B
Bristol Myers Squibb (BMY)	$109.4B
Gilead Sciences (GILD)	$105.3B
CSL (CSLLY)	$95.7B
GSK (GSK)	$80.5B
Alnylam Pharmaceuticals (ALNY)	$34.4B
Argenex SE (ARGX)	$31.7B
BioNTech SE (BNTX)	$29.2B
Biogen (BIIB)	$27B
BeiGene (BGNE)	$23.9B
Moderna (MRNA)	$23.1B
Illumina (ILMN)	$22.5B
Genmab (GMAB)	$15.5B
BioMarin Pharmaceutical (BMRN)	$13.2B
Incyte (INCY)	$13B
Exact Sciences (EXAS)	$12.6B
Vaxcyte (PCVX)	$12.4B
Insmed (INSM)	$12.4B
Bio-Techne Corp (TECH)	$11.9B
Sarepta Therapeutics (SRPT)	$11.5B
QIAGEN (QGEN)	$9.9B
Bio-Rad Laboratories (BIO.B)	$9.3B
Legend Biotech (LEGN)	$8.9B
Roivant Sciences (ROIV)	$8.4B
Ascendis Pharma (ASND)	$8.3B
Revolution Medicines (RVMD)	$7.9B
Intra-Cellular Therapies (ITCI)	$7.7B
Repligen (RGEN)	$7.7B